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Abstract
Catheter ablation has emerged as an important therapy for the management of drug refractory
symptomatic paroxysmal and persistent atrial fibrillation (AF). Although the elderly account
for the majority of patients with AF, limited data exists regarding the use of catheter ablation
for elderly patients with AF. As AF ablation has become more widespread, ablation techniques
have improved and the complication rate has decreased. As a result, referrals of elderly patients
for catheter ablation of AF are on the rise. Two retrospective analyses have recently demon-
strated that catheter ablation of AF in the elderly can safely be performed and results are
comparable to a younger population with up to 80% or more of patients maintaining sinus
rhythm at 12 months follow-up. We compared the results of 15 consecutive patients ≥ 70 years
old with symptomatic paroxysmal atrial fibrillation who underwent catheter ablation of AF at
our institution to 45 randomly sampled younger patients. The primary endpoint of our study,
presence of sinus rhythm in the absence of symptoms at 12 months follow-up, was present in
60% of elderly patients and 80% of younger patients (p = 0.17). There was no statistically
significant difference in complication rate between the younger and elderly patients. In this
article we present the results of our study and review the published literature to date regarding
the clinical efficacy and safety of catheter ablation for AF in elderly patients with paroxysmal
and persistent atrial fibrillation. (Cardiol J 2009; 16, 2: 113–120)
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Introduction
The growing epidemic of atrial fibrillation (AF)
presents new challenges for cardiovascular practi-
tioners [1]. Already the most frequently encounte-
red arrhythmia in clinical practice, the incidence and
prevalence of AF appears to be on the rise. Census
based projections estimate that by the year 2050,
12–15 million people in the United States will be
affected by atrial fibrillation [2, 3]. That AF is a di-
sease of the elderly is well established. Beginning
at age 50, the prevalence of AF almost doubles with
each decade of life; increasing from 0.5% at age 50–
–59 years to 5–7% or greater in those aged 70–79
years [4]. The median age of a patient with atrial
fibrillation in the United States is 75 years and 70%
of the AF burden in the United States is accounted
for by patients aged 65 to 85 years of age [5, 6].
Beyond the shear numbers of elderly with AF,
this population presents unique challenges to dise-
ase management. Elderly patients are more likely
to have co-morbid illnesses including hypertension,
congestive heart failure and left ventricular hyper-
trophy; placing them at increased risk for throm-
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boembolic complications with AF [7]. Age related
senescence alters the pharmacokinetics of anti-ar-
rhythmic agents making the metabolism less pre-
dictable and increasing the predilection for side-
effects, including pro-arrhythmias [8–10]. Degene-
rative changes in the cardiac conduction system that
occur with age predispose the elderly to sick sinus
syndrome, otherwise known as tachycardia-brady-
cardia syndrome [7]. This predilection for tachycar-
dia and sinus pauses (particularly during spontane-
ous cardioversion) makes pharmacologic rhythm
control difficult to achieve in elderly patients with
symptomatic paroxysmal and persistent atrial fibril-
lation. Additionally, patients with tachy-brady syn-
drome are often intolerant of atrioventricular (AV)
nodal blocking agents required for adequate rate
control, necessitating permanent pacemaker im-
plantation [10].
Until recently, there has been a paucity of data
regarding the use of catheter ablation for mainte-
nance of sinus rhythm in the elderly population (par-
ticularly those ≥ 70 years of age). Elderly patients
have largely been excluded from many AF ablation
trials because of concerns regarding safety and ef-
ficacy of catheter ablation in these patients [11–13].
With increasing life expectancy, the elderly are the
most rapidly expanding portion of our population,
making AF an even more important public health con-
cern [1, 14]. Given that elderly patients with sympto-
matic paroxysmal or persistent AF may be less tole-
rant of anti-arrhythmic agents than their younger co-
unterparts, catheter ablation for the elderly could
prove to be an important treatment strategy [7, 10].
Review of the literature
There are no randomized prospective trials
comparing the safety and efficacy of catheter abla-
tion for paroxysmal or persistent AF in the elderly
to best medical therapy or alternative strategies
such as AV node (AVJ) ablation plus pacemaker pla-
cement. Hsieh et al. [15] compared the long-term
results (> 4 years) of 71 elderly patients (> 65 ye-
ars old) with medically refractory paroxysmal AF
that were assigned to either AVJ ablation plus sin-
gle-chamber (VVI or VVIR) pacemaker placement
versus AF ablation. The AF ablation strategy con-
sisted of pulmonary vein isolation, ablation of non-
pulmonary vein foci and cavotricuspid isthmus abla-
tion. All pacemaker leads were positioned in the
right ventricular apex. One patient in each arm had
an unsuccessful ablation; thus 32 patients with AVJ
ablation and 37 patients with AF ablation were fol-
lowed for ≥ 52 months [15].
Atrial fibrillation was better controlled in the
group with AVJ ablation and pacemaker placement
than with AF ablation (100% vs. 81%, p = 0.013).
Most other outcome variables favored the AF abla-
tion strategy. In the AF ablation group, 30 (81%)
patients remained free of symptomatic AF, with
only 11% requiring anti-arrhythmic agents. 69% of
patients in the AVJ ablation plus pacemaker group
had persistent AF at the end of follow-up, compa-
red to only 8% in the AF ablation group (p < 0.001).
The incidence of congestive heart failure was signi-
ficantly higher in the AVJ plus pacemaker strategy
(53% vs. 24%, p = 0.001). Compared with pre-abla-
tion values, there was a significantly greater increase
in New York Heart Association (NYHA) class in the
pacemaker group (1.4 ± 0.7 vs. 1.7 ± 0.9, p = 0.01)
and no increase in NYHA class in the AF ablation
group (1.2 ± 0.4 vs. 1.3 ± 0.6, p = 0.2). Additionally,
the left verticular ejection fraction decreased in the
AVJ ablation group from baseline to end of follow-up
(51 ± 10% vs. 44 ± 8%, p = 0.01), but not with AF
ablation (49 ± 10% vs. 46 ± 10%, p = 0.37) [15].
There were several limitations in the report by
Hsieh et al. [15]. It was not a randomized control-
led trial comparing the two treatment arms and the
pacemaker strategy was non-physiologic. However,
it was the first study to raise the question of whe-
ther an initial attempt at AF ablation would be re-
asonable for selected elderly patients with paroxy-
smal and persistent AF prior to performing the more
permanent AV junctional ablation which leaves pa-
tients 100% pacemaker dependent. Additionally,
43 AF ablations were performed in the elderly po-
pulation without any major complications including
cardiac tamponade or cerebrovascular accident
(CVA). A recently released, randomized controlled
trial of AF ablation vs. AVJ ablation plus BiV pace-
maker placement in patients with NYHA class II and
III heart failure also favored an initial AF ablation
strategy for improving heart failure symptoms. The
mean age in this trial was 60 ± 8 years [16].
As AF ablation has become more widespread,
the clinical population has broadened, providing us
with greater insight into the potential efficacy in
older patients as well as those with more advanced
structural heart disease. Two larger analyses of
efficacy, safety and outcomes of AF ablation in sep-
tugenarians have been published. Corrado et al. [17]
reported a multi-center experience of 175 patients
older than 75 years of age who underwent catheter
ablation for symptomatic AF that was refractory to
at least one antiarrhythmic drug (AAD) between
2001 and 2006. The ablation procedure consisted
of pulmonary vein antrum isolation and isolation of
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the superior vena cava, guided by circular mapping
catheter and intracardiac echo. Patients were fol-
lowed-up at 3, 6, 9 and 12 months after the proce-
dure and every 6 months, thereafter. During the
first 5 months, patients were asked to transmit their
rhythm three times daily and when they experien-
ced symptoms of AF via an event recorder. Four-
ty-eight-hour Holter monitoring was performed at
3, 6, 9, and 12 months and then every 6 months [17].
The mean age in this study was 77 ± 6 years
with 55% of patients having paroxysmal AF and 45%
having non-paroxysmal AF. Mean ejection fraction
and left atrial size were 53 ± 7% and 4.6 ± 0.6 cm,
respectively. Mean follow-up was 20 ± 14 months.
In keeping with the results of prior AF ablation trials
in younger patients, 73% (127/174) maintained si-
nus rhythm (SR) after a single ablation procedure
(Fig. 1) [11–13]. Among the 47 patients with recur-
rences, 18 maintained SR on anti-arrhythmic agents
and 16/20 maintained SR after a 2nd procedure, with
an additional 4/20 maintaining SR on AADs after the
2nd procedure. There were only two major compli-
cations out of 194 ablations; one intra-procedure
CVA and one right hemothorax secondary to right
internal jugular central line placement. Five to six
months after successful ablation, warfarin was di-
scontinued in 138/143 patients who were in SR in
the absence of AADs. No thromboembolic events
occurred in this group during a mean follow-up of
16 ± 12 months [17].
Although the multi-center experience reported
by Corrado et al. [17] is a retrospective analysis that
is subject to a referral bias of only “healthy” septu-
genarians, there was a remarkable rate of ablation
success with 143/174 (82%) maintaining SR off
AADs after two ablation procedures. An additional
22 patients were able to maintain SR with AADs.
Thus 94% of patients were able to maintain SR at
almost 2-years follow-up with an ablation strategy
with a very low rate of major procedure related com-
plications [17]. While the ablation success rate re-
ported by Corrado et al. [17] seems almost prohibi-
tively high for an elderly population, similar results
were reported by Zado et al. [18] in their single-
center experience.
Zado et al. [18] analyzed the procedural outco-
mes of 1165 patients with drug refractory AF who
underwent 1506 ablation procedures between 2000
and 2007. The ablation procedure consisted of eli-
mination of all provocable pulmonary vein triggers
and non-pulmonary vein triggers of AF. For selec-
ted patients all four pulmonary veins were isolated.
Follow-up patient monitoring consisted of both ro-
utine office follow-up and surveillance transtelepho-
nic monitoring, as well as the ability to transmit
symptomatic episodes. Patients were stratified by
age group to < 65 years (n = 948), 65–74 years
(n = 185) and ≥ 75 years (n = 32). The peri-pro-
cedural complication rate was low with no diffe-
rence between the three age groups. In those older
than 75 years of age, there was one CVA/transient
ischemic attack (3%) and no pericardial effusions/
/tamponade requiring drainage compared to a 0.3%
CVA/transient ischemic attack rate and a 0.8% peri-
cardial effusion/tamponade rate in those < 65 years
of age.
Among the 781 patients who completed the
minimum 1-year of follow-up, there was no diffe-
rence between the groups for ablation success. AF
control rates (see Figure 2 for definition) were 89%,
Figure 1. Results from the multicenter experience reported by Corrado et al. [17] for 174 patients over 75 years of age
who underwent pulmonary vein isolation (PVI) for atrial fibrillation (AF); PM — pacemaker; AVN — atrioventricular
node, SR — sinus rhythm, AADs — antyarrhythmic drugs (reproduced with permission from [17]).
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84% and 87%, among those aged < 65, 65–74, and
> 75, respectively. There was also no difference be-
tween the percentages of patients with no reported
AF during follow-up off  anti-arrhythmic agents.
There was a trend toward less repeat procedures
among the oldest patients and more elderly patients
were maintained on AAD therapy to achieve AF con-
trol (Fig. 2). Additionally, more elderly patients were
maintained on AADs even in the absence of AF recur-
rence (5% group 1, vs. 13% group 2, vs. 14% group 3).
Our experience
We compared the procedural outcomes of
15 consecutive patients ≥ 70-year-old and 45 ran-
domly selected patients < 70-year-old who under-
went catheter ablation for paroxysmal AF between
February 2003 and February 2007 at the Strong Me-
morial Hospital, University of Rochester Medical
Center, Rochester, NY. Pulmonary vein isolation
Figure 2. Results from the single center experience re-
ported by Zado et al. [18] for the patients who comple-
ted at least 1-year follow-up from the last atrial fibrilla-
tion (AF) ablation procedure (n = 635 in group 1, n = 122
in group 2, n = 22 in group 3). Although there was
a trend towards greater use of antiarrhythmic drugs
(AADs) in older patients, there was no difference in AF
control* between the three groups, p = NS (reprodu-
ced with permission from [18]); *defined as 1) no AF
episodes on or off anti-arrhythmic therapy or 2) rare AF
(£ 6 AF episodes over the follow-up year and/or > 95%
reduction in AF burden when monitoring was compa-
red pre- and post-ablation
was performed in all patients using circumferential
applications of radiofrequency energy and verified
with a circular mapping catheter (Lasso Catheter,
Biosense Webster, Inc, Diamond Bar, Calif). The
ablation catheter used was an 8-mm nonirrigated tip
(Navistar, Biosense Webster) in 8 of the elderly and
19 non-elderly patients. When the 3.5-mm irrigated
tip catheter (Navistar Thermocool, Biosense We-
bster) became available, the remainder of the patient
procedures were performed with this catheter (n = 7
in elderly group, n = 26 in non-elderly group).
A power and temperature limit of 60 W and 60°C
was used for the non-irrigated tip catheter. A po-
wer limit of £ 35 W with a tip temperature of £ 40°C
was used for the irrigated tip catheter.
All patients were initially followed up at 3, 6
and 12 months. After the first year, they were fol-
lowed at 3–6 month intervals. Electrocardiograms
(ECGs) were performed at each follow-up visit.
Twenty-four or 48-hour Holter monitoring was per-
formed for any patient who reported recurrent
symptoms of paroxysmal AF. The primary outco-
me was presence of normal sinus rhythm (NSR)
in the absence of symptoms, on or off anti-arrhyth-
mic agents, based on ECG or Holter monitoring at
12 months of follow-up. The secondary outcome was
NSR and/or symptomatic improvement as reported
by patients during routine follow-up. Symptoms or
documentation of AF beyond 12 months were cen-
sored for the primary and secondary end-points.
Baseline characteristics of study patients were
similar (Table 1). The mean age of our elderly popu-
lation was 73 ± 2.2 years compared to a mean age of
51.9 ± 11.3 years in the younger group. A similar
percentage of younger (24%) and elderly (20%) pa-
tients underwent a repeat ablation procedure. Me-
dian clinical follow-up was 586 days and 675 days in
the young and elderly groups, respectively.
The primary outcome, presence of NSR in the
absence of symptoms, was present in 9 (60%) of
elderly patients and in 36 (80%) of younger patients
at 12-months follow-up (p = 0.17, Table 2). The
combined outcome of symptomatic improvement or
NSR was present in 80% (n = 12) of elderly patients
and 93% (n = 42) of younger patients (p = 0.16).
There were three serious complications of pericar-
dial tamponade: one in the older group and two in the
younger one (7% vs. 4%; p = 1.00). At the end of fol-
low-up, 30% of elderly patients (3/9) with successful
ablations were still using anti-arrhythmic medications
versus 8% among younger patients (p = 0.002). Ad-
ditionally, 80% of the elderly patients remained on
warfarin therapy, compared to 22% of the younger
patients (p < 0.001).
117
Darren Traub et al., Catheter ablation of AF in the elderly
www.cardiologyjournal.org
Discussion
As AF ablation has become a more mainstre-
am therapy, the number of AF ablations performed
has increased, the safety profile has improved and
patient characteristics have evolved [19–21]. Ger-
stenfeld et al. [21] reported that between 1999 and
2005, patients undergoing AF ablation have beco-
me relatively older, with more persistent and per-
manent AF and larger left atrial size. A similar trend
has been observed at our center with increasing re-
ferrals of elderly patients, as well as those with si-
gnificant structural heart disease.
Table 1. Baseline characteristics of patients undergoing atrial fibbrillation (AF) ablation by age category.
Clinical variables Age < 70 (n = 45) Age ≥ 70 (n = 15) P
Age 52 ± 11 74 ± 2 < 0.001
Female 29% 20% 0.738
Ejection fraction (%) 54 ± 8 57±6 0.105
Ejection fraction £ 45% 13% 7% 0.668
Left atrial size [mm] 41 ± 6 43±5 0.151
Left atrial size ≥ 50 mm 4% 13% 0.258
AF duration > 60 months 24% 40% 0.324
Comorbidites
Coronary artery disease 13% 20% 0.678
Hypertension 42% 40% 1.000
Diabetes 4% 7% 1.000
Medications at baseline
ACE-inhibitors 27% 40% 0.347
Beta-blockers 40% 87% 0.002
Statins 27% 40% 0.347
Flecainide 24% 13% 0.485
Tikosyn 11% 47% 0.006
Propafenone 33% 20% 0.517
Sotalol 18% 7% 0.427
Amiodarone 9% 0 0.564
None 4% 13% 0.258
The AFFIRM trial demonstrated that rate con-
trol and anti-coagulation is an acceptable manage-
ment strategy for elderly patients with AF [22]. Ho-
wever, AFFIRM did not address the needs of pa-
tients who are intolerant of AF due to loss of atrial
contraction, irregularity of QRS intervals or tachy/
/brady syndrome refractory to standard rate and
rhythm controlling agents. In the rate control arm
of AFFIRM, radiofrequency ablation to modify or
eliminate AV nodal conduction was used in 5.2% of
patients after drug failure. 12.2% of the rate con-
trol arm crossed over to rhythm control during the
study. Thus for 17.4% of the rate control arm in
Table 2. Comparison of atrial fibrillation ablation outcomes at 1 year by age category.
Age < 70 (n = 45) Age ≥ 70 (n = 15) P
NSR in the absence of symptoms at 12 months 36 (80.0%) 9 (60.0%) 0.169
NSR or symptomatic improvement 42 (93.3%) 12 (80.0%) 0.159
Remaining on anti-arrhythmic therapy (%) 7 (15.6%) 9 (60.0%) 0.002
With successful ablations who remained 3/36 (8%) 3/9 (33%) < 0.05
on anti-arrhythmic therapy (%)
Remaining on warfarin (%) 10 (22.2%) 12 (80.0%) < 0.001
Complications 2 (4.4%) 1 (6.7%) 1.000
NSR — normal sinus rhythm
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AFFIRM, use AV nodal blocking agents alone was
not a satisfactory clinical management strategy [22].
Furthermore, treatment analysis of both the
AFFIRM and DIAMOND studies suggests that the
presence of sinus rhythm is associated with impro-
ved survival [22–24]. Use of AAD in AFFIRM was
associated with increased mortality, leaving open the
question of whether a rhythm control strategy that
relies less heavily on anti-arrhythmic agents might
provide long-term survival benefit to patients [23].
In a recent editorial on management of AF in
the elderly, Curtis et al. [9] remarked that given the
potential adverse effects from long-term antithrom-
botic and anti-arrhythmic therapy in elderly pa-
tients, the role of AF ablation deserves further stu-
dy. Also mentioned was that at this point there is
too little data because elderly patients have largely
been excluded from AF ablation trials [9]. The com-
bined retrospective data from the three published
series and the experience at our center indicates
that AF ablation can be performed safely in a sep-
tuagenarian population [15, 17, 18]. While the data
reviewed above also indicates that AF ablation ap-
pears to be efficacious in a septuagenarian popula-
tion, randomized, prospective studies comparing AF
ablation to rate control and rhythm control with
AADs or both is certainly warranted.
One point of interest that emerged from re-
view of the literature to date is the trend toward
more elderly patients remaining on AADs after
ablation, even in the absence of documented re-
current AF (Table 3). A potential explanation for
this finding is that one of the goals of AF ablation
in a younger population is to negate the need for
long-term AAD therapy. For the elderly, symptom
relief with control of AF may have been the objec-
tive of ablation in these retrospective series. Ad-
ditionally, the substrate for initiation and perpe-
tuation of AF in the younger and elderly popula-
tion may differ. Aging is associated with electrical
and structural atrial remodeling including changes
in action potential shape and duration, enhanced
dispersion of repolarization, and increased atrial
fibrosis [25, 26]. Pulmonary vein isolation may not
sufficiently eliminate the triggers for AF in an el-
derly compared to a younger population; although
this remains to be proven.
Two final issues that merit discussion in regard
to AF ablation in the elderly are how to define abla-
tion success and whether or not discontinuation of
anti-coagulation therapy should be an objective of
AF ablation. Most randomized trials comparing AF
ablation to AAD therapy define ablation success as
freedom from recurrent AF at 1-year follow-up Ta
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without AAD use based on Holter monitoring and
patient reported symptoms [27–30]. From a clini-
cal perspective, achieving a significant reduction in
AF burden as reported by Zado et al. [18], regar-
dless of AAD use may be an acceptable endpoint for
a highly symptomatic elderly patient with paroxy-
mal AF; even more so with persistent AF. Howe-
ver, to truly understand the efficacy of AF ablation
in the elderly, initial randomized trials should ob-
jectively evaluate the same clinical endpoints as
those performed to date in younger populations,
specifically the ability to maintain SR off anti-arr-
hythmic agents. Perhaps pre-defined secondary
endpoints for these trials could include: a reduction
in AF episodes, ability to maintain sinus rhythm on
AADs when AADs had previously failed, symptom
reduction or other less stringent but still clinically
relevant end-points.
In the series by Corrado et al. [17], warfarin
was discontinued in 138/143 patients who mainta-
ined SR 5–6 months after AF ablation. No throm-
boembolic events occurred in this group during
a mean follow-up of 16 ± 12 months. While Corra-
do et al. [17] are to be commended for their promi-
sing results, their findings must be interpreted in
light of the yearly risk for CVA in an AF patient off
anticoagulation, which ranges from 2.8% to 6.4%
with CHADS2 scores of 1–3 [31]. Discontinuation
of warfarin following successful AF ablation in an
elderly patient is extremely appealing in concept.
Establishing the safety of this practice will require
longer follow-up of ablation patients with inquiries
specifically investigating rates and predictors of late
recurrences of AF.
Conclusions
Elderly patients have historically been under-
represented in clinical trials. As physicians we are
often left to extrapolate data and make our own
conclusions as to whether or not we feel an elderly
patient may benefit from a new technology that has
proven effective in a younger cohort. Once the tech-
nology is used in enough elderly patients, retro-
spective analyses are carried out to assess the cli-
nical efficacy. These analyses are often subject to
bias and rightfully not accepted with the same de-
gree of merit as randomized controlled trials. The
elderly represent the fastest growing segment of
our population and for this reason a conscious ef-
fort should be made to include these patients in our
clinical trials and perhaps perform trials that speci-
fically address the elderly population. Because atrial
fibrillation is a disease in which the majority of
patients are elderly, it behooves us to scientifically
investigate the efficacy of catheter ablation in this
ever expanding population. The retrospective ana-
lyses conducted to date indicate that catheter abla-
tion of AF can be safely performed in an elderly
population and appears to be beneficial. The next
step is to perform large scale, randomized trials like
AFFIRM to more definitively establish the role of
catheter ablation in treating elderly patients with
atrial fibrillation [22].
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